Blue Fin Capital’s Thermo Fisher Scientific TMO Stock Holding History

Blue Fin Capital’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$337K	Sell	672 -30	-4%	-$14.4K	0.05%	132
2026 Q1	$345K	Sell	702 -14	-2%	-$7.6K	0.06%	123
2025 Q4	$415K	Sell	716 -23	-3%	-$13K	0.06%	113
2025 Q3	$358K	Sell	739 -31	-4%	-$14.4K	0.06%	122
2025 Q2	$312K	Sell	770 -50	-6%	-$20.9K	0.05%	124
2025 Q1	$408K	Sell	820 -9	-1%	-$4.87K	0.08%	104
2024 Q4	$431K	Sell	829 -24	-3%	-$13.2K	0.08%	101
2024 Q3	$528K	Buy	853 +86	+11%	+$50.9K	0.1%	94
2024 Q2	$424K	Hold	767	–	–	0.08%	102
2024 Q1	$446K	Sell	767 -7	-0.9%	-$3.93K	0.1%	99
2023 Q4	$411K	Hold	774	–	–	0.11%	99
2023 Q3	$392K	Sell	774 -2	-0.3%	-$1.07K	0.11%	98
2023 Q2	$405K	Hold	776	–	–	0.12%	102
2023 Q1	$423K	Buy	776 +11	+1%	+$6.2K	0.14%	96
2022 Q4	$421K	Hold	765	–	–	0.15%	94
2022 Q3	$388K	Hold	765	–	–	0.15%	91
2022 Q2	$415K	Hold	765	–	–	0.15%	91
2022 Q1	$451K	Sell	765 -55	-7%	-$31.6K	0.13%	92
2021 Q4	$547K	Hold	820	–	–	0.15%	86
2021 Q3	$468K	Hold	820	–	–	0.14%	88
2021 Q2	$413K	Hold	820	–	–	0.13%	91
2021 Q1	$374K	Buy	+820	New	+$391K	0.13%	89

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Blue Fin Capital's TMO Position: Q2 2026 in Review

Blue Fin Capital reduced its Thermo Fisher Scientific (TMO) stake by 4.3% in Q2 2026, selling an estimated $14.4K and leaving 672 shares worth $337K. The position accounts for 0.05% of the portfolio, ranked #132.

Blue Fin Capital first reported a position in TMO in Q1 2021 and has held it in 22 quarters since. The position peaked at $547K in Q4 2021. 2,626 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Blue Fin Capital held 672 shares of Thermo Fisher Scientific worth $337K as of Q2 2026.
Blue Fin Capital sold 30 Thermo Fisher Scientific shares in Q2 2026, an estimated $14.4K.
Thermo Fisher Scientific made up 0.05% of Blue Fin Capital's portfolio in Q2 2026, its #132 holding.
Blue Fin Capital first reported a position in Thermo Fisher Scientific in Q1 2021 and has held it in 22 quarters since.
Blue Fin Capital's Thermo Fisher Scientific position peaked at $547K in Q4 2021.
2,626 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Blue Fin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.